$GHSI
Guardion Health Sciences Inc Stock $ghsi

$ghsi Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040487 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$2.936M	$3.337M	$2.664M
YoY Change	7.68%	25.29%	-15.41%
Cost Of Revenue	$1.586M	$1.877M	$1.575M
YoY Change	-11.4%	19.14%	-10.52%
Gross Profit	$1.350M	$1.460M	$1.088M
YoY Change	44.17%	34.19%	-21.6%
Gross Profit Margin	45.97%	43.76%	40.85%
Selling, General & Admin	$2.042M	$2.222M	$2.758M
YoY Change	-6.7%	-19.42%	-32.32%
% of Gross Profit	151.28%	152.2%	253.46%
Research & Development	$80.00	$10.67K	$60.20K
YoY Change	-99.75%	-82.27%	270.94%
% of Gross Profit	0.01%	0.73%	5.53%
Depreciation & Amortization	$9.420K	$0.00	$14.72K
YoY Change	-96.88%	-100.0%	-95.36%
% of Gross Profit	0.7%	0.0%	1.35%
Operating Expenses	$2.042M	$2.233M	$2.828M
YoY Change	-8.01%	-21.02%	-30.89%
Operating Profit	-$692.2K	-$772.9K	-$1.739M
YoY Change	-46.07%	-55.56%	-35.66%
Interest Expense	$1.382M	$1.150M	$43.28K
YoY Change	-43.47%	2557.12%
% of Operating Profit
Other Income/Expense, Net		$1.146M	$916.5K
YoY Change		24.99%
Pretax Income	$424.7K	$370.0K	-$1.696M
YoY Change	-104.77%	-121.81%	-43.74%
Income Tax
% Of Pretax Income
Net Earnings	$424.7K	$372.6K	-$1.696M
YoY Change	-104.31%	-121.97%	-43.74%
Net Earnings / Revenue	14.47%	11.17%	-63.68%
Basic Earnings Per Share		$0.29	-$0.03
Diluted Earnings Per Share	$0.34	$0.29	-$27.53K
COMMON SHARES
Basic Shares Outstanding	1.275M shares	1.273M shares	61.60M shares
Diluted Shares Outstanding		1.273M shares	1.232M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.360M	$7.660M	$12.95M
YoY Change	-60.02%	-40.83%	22.61%
Cash & Equivalents	$6.360M	$7.657M	$12.95M
Short-Term Investments			$0.00
Other Short-Term Assets	$573.8K	$970.0K	$1.038M
YoY Change	-16.59%	-6.59%	-16.71%
Inventory	$2.677M	$2.451M	$1.953M
Prepaid Expenses			$1.038M
Receivables	$2.274M	$1.766M	$1.874M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.88M	$12.84M	$17.81M
YoY Change	-45.07%	-27.91%	19.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.25K	$38.14K	$53.76K
YoY Change	-31.96%	-29.05%	-82.01%
Goodwill
YoY Change
Intangibles	$0.00		$10.36M
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$33.25K	$38.14K	$10.42M
YoY Change	-31.96%	-99.63%	-56.13%
TOTAL ASSETS
Total Short-Term Assets	$11.88M	$12.84M	$17.81M
Total Long-Term Assets	$33.25K	$38.14K	$10.42M
Total Assets	$11.92M	$12.88M	$28.23M
YoY Change	-45.04%	-54.38%	-26.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$614.1K	$881.6K	$1.041M
YoY Change	-59.55%	-15.28%	-12.03%
Accrued Expenses	$704.9K	$550.1K	$683.2K
YoY Change	26.26%	-19.48%	-13.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.319M	$1.432M	$1.733M
YoY Change	-67.12%	-17.4%	-12.02%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.453M	$3.740M	$0.00
YoY Change	-45.57%
Total Long-Term Liabilities	$2.453M	$3.740M	$0.00
YoY Change	-45.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.319M	$1.432M	$1.733M
Total Long-Term Liabilities	$2.453M	$3.740M	$0.00
Total Liabilities	$3.772M	$5.176M	$1.733M
YoY Change	-55.72%	198.64%	-12.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.57M	-$93.99M	-$84.82M
YoY Change	-0.17%	10.81%
Common Stock	$1.275K	$1.275K	$61.60K
YoY Change	0.63%	-97.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.146M	$7.702M	$26.49M
YoY Change
Total Liabilities & Shareholders Equity	$11.92M	$12.88M	$28.23M
YoY Change	-45.04%	-54.38%	-26.89%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	$424.7K	$372.6K	-$1.696M
YoY Change	-104.31%	-121.97%	-43.74%
Depreciation, Depletion And Amortization	$9.420K	$0.00	$14.72K
YoY Change	-96.88%	-100.0%	-95.36%
Cash From Operating Activities	-$1.320M	-$760.0K	-$1.282M
YoY Change	-3.23%	-40.72%	-28.48%
INVESTING ACTIVITIES
Capital Expenditures	$3.790K	$0.00	-$3.170K
YoY Change		-100.0%	-95.81%
Acquisitions
YoY Change
Other Investing Activities	$19.93K	$0.00	$10.01M
YoY Change		-100.0%	-14381.09%
Cash From Investing Activities	$16.14K	$0.00	$10.00M
YoY Change		-100.0%	-6964.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.100K	60.00K	0.000
YoY Change	-100.05%
NET CHANGE
Cash From Operating Activities	-1.320M	-760.0K	-1.282M
Cash From Investing Activities	16.14K	0.000	10.00M
Cash From Financing Activities	-2.100K	60.00K	0.000
Net Change In Cash	-1.306M	-700.0K	8.721M
YoY Change	-144.12%	-108.03%	-549.89%
FREE CASH FLOW
Cash From Operating Activities	-$1.320M	-$760.0K	-$1.282M
Capital Expenditures	$3.790K	$0.00	-$3.170K
Free Cash Flow	-$1.324M	-$760.0K	-$1.279M
YoY Change	-2.95%	-40.58%	-25.52%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001642375
CY2023Q3	us-gaap	Restricted Cash RestrictedCash		usd
CY2023Q3	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent		usd
CY2023Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills		usd
	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills		usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	GHSI	Issuance Of Vested Restricted Stock Net IssuanceOfVestedRestrictedStockNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	GHSI	Recording Of Initial Warrant Derivative Liability RecordingOfInitialWarrantDerivativeLiability		usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38861
	dei	Entity Registrant Name EntityRegistrantName	GUARDION HEALTH SCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4428421
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2925 Richmond Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77098
	dei	City Area Code CityAreaCode	800
	dei	Local Phone Number LocalPhoneNumber	873-5141
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	GHSI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1275238	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7657309	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10655490	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	5250000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1766028	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1924353	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2450650	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	965644	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	687933	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	12839631	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21637197	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38144	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	48871	usd
CY2023Q3	us-gaap	Assets Assets	12877775	usd
CY2022Q4	us-gaap	Assets Assets	21686068	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	881600	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1518052	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	550057	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	558287	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3807	usd
CY2022Q4	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent	1931400	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1431657	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4011546	usd
CY2023Q3	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	3744400	usd
CY2022Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	4506600	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5176057	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8518146	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	5250000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1275239	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1275239	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1267340	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1267340	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1275	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1267	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101691430	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101640955	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93990987	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93724300	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7701718	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12877775	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21686068	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3337190	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2663550	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9312695	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8323382	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1876938	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1575366	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5267874	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4739197	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	1460252	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	1088184	usd
	us-gaap	Gross Profit GrossProfit	4044821	usd
	us-gaap	Gross Profit GrossProfit	3584185	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10671	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60203	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150604	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	162418	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	318734	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	526193	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1332469	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1583349	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1903761	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2231895	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5811315	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7875894	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9287	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9287	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2233166	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2827578	usd
	us-gaap	Operating Expenses OperatingExpenses	7294388	usd
	us-gaap	Operating Expenses OperatingExpenses	9655205	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-772914	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1739394	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3249567	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6071020	usd
CY2023Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	1050800	usd
CY2022Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	873200	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2693600	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	3548300	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	94747	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	43282	usd
	us-gaap	Interest Income Other InterestIncomeOther	289280	usd
	us-gaap	Interest Income Other InterestIncomeOther	54458	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1145547	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	916482	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2982880	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3602758	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	372633	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-822912	usd
	us-gaap	Net Income Loss NetIncomeLoss	-266687	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2468262	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.27
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1273486	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1273486	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1232016	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1232016	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1273249	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1273249	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1083924	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1083924	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7917922	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25182	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5329	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	533091	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8481524	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-73456	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5388	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1172411	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7241045	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	27943	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2194	usd
CY2023Q3	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	57903	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	372633	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7701718	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22297800	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	85963	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	59906	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8834898	usd
CY2022Q1	GHSI	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1134040	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8783800	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5300987	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18327820	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	61818	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	11585	usd
CY2022Q2	GHSI	Issuance Of Vested Restricted Stock Net IssuanceOfVestedRestrictedStockNet	-24011	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	3655637	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	22032849	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	22032849	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	44101	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5447	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-822912	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-822912	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	21259485	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	21259485	usd
	us-gaap	Net Income Loss NetIncomeLoss	-266687	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2468262	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	14518	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	946397	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9287	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	-20331	usd
	GHSI	Fair Value Of Vested Stock Options FairValueOfVestedStockOptions	191882	usd
	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	12911	usd
	GHSI	Fair Value Of Vested Restricted Common Stock FairValueOfVestedRestrictedCommonStock	76938	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2693600	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3548300	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-158325	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41679	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-668771	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1585240	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	277711	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	258560	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-636452	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	799249	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3807	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16556	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8230	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-212319	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3052293	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6082906	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3791	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5569	usd
	GHSI	Payments To Acquire Treasury Bills PaymentsToAcquireTreasuryBills	77591741	usd
	GHSI	Proceeds From Sale Of Treasury Bills ProceedsFromSaleOfTreasuryBills	82587364	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3791	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4990054	usd
	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	5250000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	8834899	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	57903	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1134040	usd
	GHSI	Issuance Of Vested Restricted Stock Net IssuanceOfVestedRestrictedStockNet	24011	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5192097	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9944928	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8248181	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8852076	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15905490	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4093927	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7657309	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12946003	usd
	GHSI	Recording Of Initial Warrant Derivative Liability RecordingOfInitialWarrantDerivativeLiability	8783800	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3249567	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3052293	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7657309	usd
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-fifty (1:50) reverse stock split
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zDy0VQLc68c5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zlSoTsYIQnH5">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing the warrant derivative liability, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1996	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3337190	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2663550	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9312695	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8323382	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3337190	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2663550	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9312695	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8323382	usd
CY2023Q3	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1759260	usd
CY2022Q3	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1876259	usd
	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	4339388	usd
	GHSI	Third Party Outsourcing ThirdPartyOutsourcing	1932967	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	279457	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	385010	usd
	us-gaap	Advertising Expense AdvertisingExpense	1109310	usd
	us-gaap	Advertising Expense AdvertisingExpense	1264740	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_z2gC0p0MKqc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zdKpZlrEoGhh">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue. </i>During the three months ended September 30, 2023, the Company had two customers that accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zhDwtpT526g2" title="Concentration risk percentage">68</span>% of total revenue. During the nine months ended September 30, 2023, the Company had two customers that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zhhXRAxy0WP7" title="Concentration risk percentage">64</span>% of total revenue. During the three months ended September 30, 2023, the largest customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zd7KzmG97U21" title="Concentration risk percentage">47</span>% of the Company’s total revenue, and the second largest customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondLargestCustomerMember_z9o3iQPpQv0g" title="Concentration risk percentage">21</span>% of the Company’s total revenue. During the nine months ended September 30, 2023, the largest customer accounted for <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zKbpyEoq72s9" title="Concentration risk percentage">50</span>% of the Company’s total revenue and the second largest customer accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--SecondLargestCustomerMember_z2qfzyn7P7Ta" title="Concentration risk percentage">14</span>%. During the three months ended September 30, 2022, the Company had one customer that accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zSp0gKb4xaE5" title="Concentration risk percentage 1">57</span>% of total revenue. During the nine months ended September 30, 2022, the Company had one customer that accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zJDb9zSC5oB7" title="Concentration risk percentage 1">56</span>% of the Company’s total revenue. No other customer accounted for more than <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember_zHLYrQbjeJm4" title="Concentration risk percentage 1"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember_zI14vZtEYf5c" title="Concentration risk percentage 1"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember_zb17vhLIjWz4" title="Concentration risk percentage 1"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember_zQleJlejLRK7" title="Concentration risk percentage 1">10</span></span></span></span>% of revenue during the three months and nine months ended September 30, 2023 and 2022. The Company sells the majority of its products to one of the largest retailers in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts receivable</i>. As of September 30, 2023, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--RangeAxis__srt--MaximumMember_z7GMGTFPMqXa" title="Concentration Risk, Percentage">61</span>% of its accounts receivable and one customer that accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember__srt--RangeAxis__srt--MinimumMember_zIEgJN1dTLv1" title="Concentration Risk, Percentage">13</span>% of its accounts receivable. As of December 31, 2022, the Company had accounts receivable from one customer which comprised approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zwMygCN5jQA4" title="Concentration Risk, Percentage">88</span>% of its accounts receivable. No other customer accounted for more than <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zlnjmNrvDwN6" title="Concentration Risk, Percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zw0Hmv1KCSMk" title="Concentration Risk, Percentage">10</span></span>% of accounts receivable as of September 30, 2023 and December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchases from vendors</i>. During the three months and nine months ended September 30, 2023 and 2022, the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zHq4cR6EdoWh" title="Concentration Risk, Percentage">59</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zSUpPDpbGfxf" title="Concentration Risk, Percentage">47</span>% of all purchases during the three months and nine months ended September 30, 2023, respectively. Total purchases from this manufacturer accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_zP1VvnmD0sK8" title="Concentration Risk, Percentage">49</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsTotalMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneManufacturerMember_z6QNpZBWNSIk" title="Concentration Risk, Percentage">46</span>% of all purchases during the three months and nine months ended September 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts payable</i>. As of September 30, 2023, one vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_z9cMigOhDdx1" title="Concentration Risk, Percentage">84</span>% of total accounts payable. As of December 31, 2022, one vendor accounted for <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneVendorMember_zx9jaQQDqrx6" title="Concentration Risk, Percentage">88</span>% of the total accounts payable. One other vendor accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zp5lHpXdoEwe" title="Concentration risk, percentage">13</span>% of total accounts payable as of September 30, 2023. No other vendor accounted for more than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherVendorMember__srt--RangeAxis__srt--MinimumMember_zbjXEAdW4g65" title="Concentration risk, percentage">10</span>% of accounts payable as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash and cash equivalents.</i> Cash and cash equivalents consist of funds deposited with BMO Harris Bank (“BMO”), which is a major, established, high quality financial institution, in short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. The Company has an overnight investment feature established with BMO whereby the Company’s cash is swept into a Money Market Mutual Fund managed by Goldman Sachs Asset Management. This fund invests solely in high quality U.S. government issued securities. As of September 30, 2023, $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20230930_zPy2r1KPz24h" title="Cash and cash equivalents balance">7,657,309</span> included in cash and cash equivalents was held in the Goldman Sachs Financial Square Government Institutional Fund, a fund that is not insured by the Federal Deposit Insurance Corporation (the “FDIC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zr3fcQx3PEXg" title="Cash FDIC insured amount">250,000</span> and $<span id="xdx_90F_ecustom--CashSIPCInsuredAmount_iI_c20230930_z7Itc4J5KB49" title="Cash SIPC insured amount">500,000</span>, respectively. The Company believes that no significant concentration of credit risk exists with respect to its cash balances because of the creditworthiness and financial viability of the financial institutions that hold such cash balances. The Company has not experienced any losses to date resulting from this policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7657309	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	GHSI	Cash Sipc Insured Amount CashSIPCInsuredAmount	500000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	800046	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1504839	shares
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3744400	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2693600	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3744400	usd
CY2023Q3	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	3744400	usd
CY2022Q4	GHSI	Warrant Derivative Liability Current WarrantDerivativeLiabilityCurrent	1931400	usd
CY2022Q4	GHSI	Warrant Derivative Liability Non Current WarrantDerivativeLiabilityNonCurrent	4506600	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	35405	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	49637	usd
CY2023Q3	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	2415245	usd
CY2022Q4	us-gaap	Inventory Finished Goods And Work In Process Net Of Reserves InventoryFinishedGoodsAndWorkInProcessNetOfReserves	3069784	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	2450650	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3119421	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11900000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10065833	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	297500	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	892500	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2700	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	24257	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	22221	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3807	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3744400	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	6438000	usd
CY2022Q4	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The Certificates of Designation for the Preferred Stock provided that the Preferred Stock had no voting rights other than the right to vote on the Amendment and as a class on certain other specified matters, and, with respect to the Series D Certificate of Designation, the right to cast 1,000,000 votes per share of Series D Preferred Stock on the Reverse Stock Split proposal. The Amendment required the approval of the majority of the votes associated with the Company’s outstanding stock entitled to vote on the proposal. On January 5, 2023, the Amendment to authorize a reverse split of the Common Stock was approved at a special meeting of the Company’s stockholders. Following the meeting, the board of directors approved a one-for-fifty (1-for-50) reverse split of the Company’s issued and outstanding shares of common stock (see Note 2).
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4750000	usd
CY2022	GHSI	Proceeds From Issuance Of Private Placement Additional ProceedsFromIssuanceOfPrivatePlacementAdditional	500000	usd
CY2022	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.05	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	779052	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13294	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	217.05
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11336	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.22
	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1	P9Y18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	595	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	197.70
	GHSI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Forfeitures Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresWeightedAverageRemainingContractualTerm1	P7Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3458	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	357.53
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20577	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	77.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M20D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10096	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	149.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20577	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10096	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	20331	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	191882	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	10096	shares
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	153000	usd
	GHSI	Share Based Compensation Amortized Period ShareBasedCompensationAmortizedPeriod	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	7.38
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	13700	usd
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-23-040487-index-headers.html	Edgar Link	pending
0001493152-23-040487-index.html	Edgar Link	pending
0001493152-23-040487.txt	Edgar Link	pending
0001493152-23-040487-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
ghsi-20230930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ghsi-20230930_cal.xml	Edgar Link	unprocessable
ghsi-20230930_def.xml	Edgar Link	unprocessable
ghsi-20230930_lab.xml	Edgar Link	unprocessable
ghsi-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GHSI
Guardion Health Sciences Inc Stock $ghsi

2023 Q4 Form 10-Q Financial Statement

#000149315223040487 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI Guardion Health Sciences Inc Stock $ghsi

2023 Q4 Form 10-Q Financial Statement

#000149315223040487 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GHSI
Guardion Health Sciences Inc Stock $ghsi